Canadian Men’s Health Foundation expands MindFit Toolkit to support more men with anxiety and depression
19 janv. 2023 08h00 HE
|
Canadian Men's Health Foundation
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Men’s Health Foundation (CMHF) announced today new and expanded mental health resources for their MindFit Toolkit...
Signati™ Medical, Inc. Completes Acquisition of SuperiorVAS Intellectual Property and Technology
09 déc. 2022 09h00 HE
|
Signati Medical Inc.
Providence, RI, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Signati™ Medical, Inc. today announced that it has completed the acquisition of all of the intellectual property and technology of SuperiorVAS, LLC,...
Lifestyle changes and nutritional supplements improve the Cap-Score™ and male fertility
26 oct. 2022 09h30 HE
|
Androvia LifeSciences
New study shows a man’s overall health, in combination with taking nutritional supplements, is associated with enhanced sperm capacitation ability, as measured by Cap-Score, and an increase in male...
The Cap-Score™ is a more sensitive indicator of male fertility across age groups than traditional semen analysis
26 oct. 2022 09h00 HE
|
Androvia LifeSciences
New study demonstrates the value of using the Cap-Score Test to assess the fertilizing ability in men of all ages who are seeking fertility assistance Cap-Score is consistently low in men of all age...
Base Healthcare Launches Innovative Platform for Men with Testosterone Deficiency
18 oct. 2022 08h00 HE
|
Base Healthcare
RALEIGH, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Base Healthcare today announced the official launch of its subscription-based men’s virtual health platform, which focuses on foundational health and...
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
21 sept. 2022 11h08 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
18 août 2022 16h05 HE
|
Clarus Therapeutics Holdings, Inc.
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year ...
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
28 juil. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
09 juin 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
Signati™ Medical, Inc. Debuts Innovative Bipolar Radio Frequency Sealing Platform at American Urological Association (AUA) Annual Meeting
24 mai 2022 09h00 HE
|
Signati Medical Inc.
Providence, RI, May 24, 2022 (GLOBE NEWSWIRE) -- Signati™ Medical, Inc. is pleased to announce the unveiling of their innovative Sealed Vasectomy Procedure at this year’s AUA Annual Meeting in New...